hero section gradient
16 handpicked stocks

Garage Innovators

Meet the companies that are inventing tomorrow, today. These stocks represent businesses with exceptional in-house research and development, carefully selected by professional analysts for their ability to create breakthrough products and technologies from within.

Author avatar

Han Tan | Market Analyst

Published on June 17

Your Basket's Financial Footprint

Summary of the Garage Innovators basket market capitalisation and investor key takeaways.

Key Takeaways for Investors:
  • Large-cap dominance suggests generally lower volatility and closer tracking of broader market movements, implying reduced idiosyncratic risk.
  • Suitable as a core, diversified portfolio holding rather than a speculative allocation; complements long-term equity exposure.
  • Likely steady, long-term value appreciation rather than short-term explosive gains; growth should be moderate and gradual.
Total Market Cap
  • PTC: $24.50B

  • LRCX: $182.63B

  • ROP: $55.37B

  • Other

About This Group of Stocks

1

Our Expert Thinking

Companies that prioritize internal innovation over acquisitions often develop stronger competitive advantages. These firms invest heavily in R&D to create proprietary technologies and intellectual property that can lead to market-defining inventions and potentially superior long-term returns.

2

What You Need to Know

This collection spans multiple sectors including software, materials science, biotechnology, and semiconductor technology. These growth-oriented stocks may experience volatility as they develop new technologies, but they offer significant upside potential from successful innovations that transform their markets.

3

Why These Stocks

Each company was selected for its proven track record of transforming internal research into commercial success. They demonstrate exceptional R&D investment relative to their size, strong patent portfolios, and a history of launching groundbreaking products that were developed organically rather than acquired.

Why You'll Want to Watch These Stocks

💡

The Innovation Premium

Companies that create their own technologies tend to command higher valuations over time. These stocks represent businesses that aren't just following trends but creating them from scratch.

🔬

The Next Big Discovery

Many of these R&D-focused companies are working on breakthroughs that could transform entire industries. Getting in early means potential access to market-defining innovations before they hit the mainstream.

🛡️

Built-In Protection

Companies with strong intellectual property developed in-house often have better defensibility against competitors. Their patents and proprietary technology create moats that can protect profits for years or even decades.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Beverage Stocks: What's Next After Coca-Cola's Pivot

Beverage Stocks: What's Next After Coca-Cola's Pivot

Coca-Cola is discontinuing its historic Minute Maid frozen products to focus on faster-growing beverage categories. This strategic shift highlights a broader investment opportunity in companies leading the market's transition toward healthier, more convenient, and functional drinks.

Factory Automation Stocks | Rising Labor Costs Trend

Factory Automation Stocks | Rising Labor Costs Trend

Volkswagen's recent agreement with the UAW signals a new era of rising labor costs for foreign automakers in the U.S. This theme focuses on companies poised to benefit as the industry increases investment in factory automation and robotics to enhance productivity.

Blood Thinner Breakthrough Explained | Market Overview

Blood Thinner Breakthrough Explained | Market Overview

Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.

Frequently Asked Questions